Targeted therapy for chronic lymphocytic leukemia: current status and future directions

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chronic lymphocytic leukemia (CLL) is a common leukemia where most patients initially respond to chemo-immunotherapy.
• However, long-term remission is not achieved, and CLL complications remain a leading cause of death.

Purpose of the Study:

• This review discusses recent advancements in targeted therapy for CLL.
• It highlights the evolution of treatment strategies beyond traditional chemo-immunotherapy.

Main Methods:

• The review examines the evolution of antibody therapy in CLL.
• It explores strategies for targeting effector T cells, inhibiting B-cell receptor signaling, and targeting apoptosis mediators.

Main Results:

• Targeted therapies have shown significant clinical responses in patients with refractory CLL.
• These approaches leverage a deeper understanding of CLL biology.

Conclusions:

• Targeted therapy represents a significant evolution in CLL treatment.
• It holds promise for managing CLL without chemotherapy in the future.